9939 — Kintor Pharmaceutical Share News
0.000.00%
Last trade - 00:00- HK$750.48m
- HK$870.57m
- CNY32.68m
Brief: Kintor Pharmaceutical Announces Inclusion Of Kintor As Constituent Of Hang Seng Composite Index
HK-listed Kintor Pharmaceutical jumps on COVID-19 deal with Shanghai Fosun
Brief: Kintor Pharma Says Unit Entered Proxalutamide Licensing Agreement
Brief: Kintor Pharmaceutical Received Investigational New Drug Clearance By Us FDA For GT20029 In US
Covid Science: Experimental prostate cancer drug may improve COVID-19 survival; younger patients report long lasting symptoms
HK-listed Kintor Pharma hits 2-week low on discounted share sale
Brief: Kintor Pharmaceutical Says A Shareholder To Sell 18.2 Mln Shares At A Price Of HK$64.50/Share
Brief: Kintor Pharmaceutical Says US FDA Greenlighted Phase III Clinical Trial Of Proxalutamide
Insight: The man behind Brazil's search for miracle COVID-19 cures
Insight: The man behind Brazil's search for miracle COVID-19 cures
What you need to know about the coronavirus right now
Chinese firm's COVID-19 drug claims draw skepticism (updated)
HK-listed Kintor slips after report says COVID-19 drug claims draw skepticism
Chinese firm's COVID-19 drug claims draw scientists' skepticism
Brief: Legend Holdings' Long Position In Kintor Pharmaceutical Falls To 6.99% - HKEX Filing
Brief: Kintor Pharmaceuticals Announced Successful Dosing Of The First Batch Of Patients For Acne Vulgaris Phase I/Ii Clinical Trial Of Pyrilutamide
Brief: Kintor Pharmaceutical Says Gt20029's Investigational New Drug Applications Approved By CDE Of NMPA
Brief: Kintor Pharma- Ar-Protac (Gt20029) Approved For Acne And Androgenic Alopecia Clinical Trials In China
Brief: Kintor Pharmaceutical And Visum Announced Strategic Partnership To Expand Proxalutamide Manufacturing